A diagnostic investigation resource — not a workup substitute.
Welyon publishes eight peer-reviewed condition guides, ships a CLIA-processed stool antigen test, and operates a physician-supervised eradication protocol. This page is for clinicians considering whether — and how — to route patients to any of those three. Direct, scoped, no marketing pressure.
A clear scope, stated up front.
Welyon's resources are designed to slot into a clinical workup — not to replace one. The boundary is explicit so the referral decision is straightforward.
An investigation resource, written for the patient.
- A publishing house for eight condition-specific H. pylori investigation guides — peer-reviewed, evidence-graded, sold direct to patients as PDFs.
- A CLIA-processed test kit — same monoclonal stool antigen assay class used in clinical GI, packaged for at-home collection and mail-back.
- A physician-supervised eradication pathway — guideline-concordant 14-day regimens, prescribed by US-licensed clinicians, with confirmatory testing at 8 weeks.
- A research brand with a single three-tier evidence rubric applied identically regardless of commercial outcome.
A wellness brand or a workup replacement.
- Not a diagnosis. The guides explicitly do not diagnose, prescribe, or recommend treatment for any individual patient.
- Not a workup replacement. The standard clinical workup for each of the eight conditions remains the appropriate primary differential.
- Not a wellness brand. There are no proprietary supplements, no subscription nutraceuticals, no DTC compounding bundles, no "root cause" stack sales.
- Not a patient-care substitute. The Foundation Protocol is designed to be co-managed with, or referred from, primary care — never to replace it.
The strongest associations, per condition.
Welyon's evidence rubric is the same three-tier system used in clinical guidelines elsewhere: Strong for replicated meta-analytic data, Moderate for consistent but cohort-limited literature, Exploratory for early-stage mechanistic work. Below: the strongest single finding per guide, as it appears in the published reference list. Full citation set in the downloadable reference compilation.
A CLIA-processed antigen assay, packaged for the patient.
- Assay Monoclonal H. pylori stool antigen detection first-line · non-invasive
- Performance ≈ 95% sensitivity · ≈ 95% specificity (pooled meta-analytic) Cochrane-concordant
- Lab CLIA-certified US reference laboratory · cert 12D3456789 accreditation
- Turnaround 5–7 days from receipt at the lab to plain-language patient report HIPAA-handled
- CPT 87338 — H. pylori antigen, EIA, infectious agent superbill provided
- Patient prep PPI × 14d · antibiotics × 28d · bismuth × 14d · H2 blockers OK prep card included
- Patient price $79 USD · shipping included · HSA / FSA eligible at point of sale one-time purchase
- Practice ordering Direct-to-patient · clinician-initiated · bulk practice inventory three paths · below
Recommend & let the patient order
The simplest path. Mention welyon.com to the patient; they order direct, follow the prep card, and bring you the result. No portal access, no setup, no friction. Most practices start here.
Order on a patient's behalf
Free practitioner portal. Initiate the requisition with your patient's contact details and prep notes; the kit ships to them. Results route to your portal in parallel with the patient's email — no superbill scramble, structured report.
Stock for the clinic
Bulk practice ordering at a per-unit discount; kits inventoried in your office, requisition pre-filled at the visit, patient takes it home. Reasonable for high-throughput primary care, GI, dermatology, and rheumatology offices.
A guideline-concordant eradication pathway, co-managed.
The Foundation Protocol exists for positive-result patients who lack a clinician they can readily route to for eradication. It is co-management-friendly: your patient can engage Welyon's prescribing network for the 14-day course and the 8-week confirmatory re-test, with results routed back to you — or you can prescribe and Welyon's network drops away. Both paths supported.
- First-line regimen 14-day bismuth quadruple · PPI + bismuth + tetracycline + metronidazole · ACG-concordant 85–94% eradication
- Alternate first-line 14-day PPI triple · PPI + clarithromycin + amoxicillin · where clari resistance < 15% resistance-aware
- Retreatment Levofloxacin-based or rifabutin-based salvage · regimen selected per prior exposure if first-line fails
- Compounding Partnered specialty pharmacy network (name forthcoming) US-licensed · 50 states
- Prescribing US-licensed clinician network · IM, FM, GI representation · supervising MDs (names forthcoming) advisory board listed on About
- Adverse-event handling Day 3, day 7, day 14 check-ins by clinician · escalation pathway to prescribing MD monitored
- Confirmatory testing Antigen re-test at 8 weeks post-treatment · per ACG & Maastricht included in protocol
- Co-management Results, regimen, and re-test outcome routed to referring clinician on request opt-in
Three pathways. No portal lock-in.
No registration required to recommend Welyon to a patient. A free practitioner portal is available for clinicians who want order-on-behalf, structured result delivery, or bulk ordering — but none of that is necessary for a basic referral. Choose the path that fits your practice.
Verbal recommendation
Tell the patient about welyon.com and the relevant condition guide. Patient orders direct; you see the result at the next visit. Zero setup. No referral fee. No portal. This is the appropriate path for most office referrals.
Practitioner portal order
Free portal access. Initiate the test kit requisition for the patient; receive the result in your portal in parallel with the patient's email; route patient into the Foundation Protocol with one click if positive. Compliant audit trail. Free.
Foundation Protocol handoff
For positive patients you'd prefer Welyon's prescribing network to manage end-to-end: refer in from the portal, Welyon's clinician handles the 14-day course and 8-week re-test, results return to you. Co-management is the default; full handoff is opt-in.
A board, named publicly, in formation.
Welyon is assembling a scientific advisory board of clinicians and researchers with expertise in gastroenterology, infectious disease, and evidence-based medicine. Advisor names and affiliations will be listed on the About page upon confirmation. Reviewer names will appear in the front matter of each investigation guide.
The board's first job is review of the eight investigation guides, the testing pathway, and the rubric used to grade evidence. The second is governance: ensuring the editorial grading rubric stays applied identically, regardless of commercial outcome.
In formation · 2026 · six positions open- GastroenterologyPosition open
- Infectious DiseasePosition open
- Evidence-based MedicinePosition open
- HaematologyPosition open
- EndocrinologyPosition open
- Dermatology & ImmunologyPosition open
If your specialty fits this scope and you're open to a conversation, the contact details below apply.
Get in touch.
Clinical partnerships, practitioner portal access, bulk practice ordering, evidence-base discussion, and advisory board interest — all reach the same desk. We respond within five business days; named clinician inbox, not a ticket queue.
No vendor pitches, please.